Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs

Bueno, 2011, MicroRNAs and the cell cycle, Biochim Biophys Acta, 1812, 592, 10.1016/j.bbadis.2011.02.002 d’Adda di Fagagna, 2014, A direct role for small non-coding RNAs in DNA damage response, Trends Cell Biol, 24, 171, 10.1016/j.tcb.2013.09.008 Jovanovic, 2006, MiRNAs and apoptosis: RNAs to die for, Oncogene, 25, 6176, 10.1038/sj.onc.1209912 Brown, 1999, The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain memorial award lecture, Cancer Res, 59, 5863 Lacombe, 2017, Emergence of miR-34a in radiation therapy, Crit Rev Oncol Hematol, 109, 69, 10.1016/j.critrevonc.2016.11.017 John-Aryankalayil, 2012, Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells, Radiat Res, 178, 105, 10.1667/RR2703.1 Li, 2011, Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells, Prostate, 71, 567, 10.1002/pros.21272 Josson, 2008, Radiation modulation of microRNA in prostate cancer cell lines, Prostate, 68, 1599, 10.1002/pros.20827 Huang, 2013, MiRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1, Cancer Res, 73, 6972, 10.1158/0008-5472.CAN-13-1657 Wang, 2016, Hypoxia-responsive mir-301a and mir-301b promote radioresistance of prostate cancer cells via downregulating NDRG2, Med Sci Monit, 22, 2126, 10.12659/MSM.896832 O'Kelly, 2012, MicroRNAs as putative mediators of treatment response in prostate cancer, Nat Rev Urol, 10.1038/nrurol.2012.104 Leung, 2014, Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment, Oncol Rep, 31, 1067, 10.3892/or.2014.2988 Lim, 2015, Recent advances in developing molecular tools for targeted genome engineering of mammalian cells, BMB Rep, 48, 6, 10.5483/BMBRep.2015.48.1.165 Bristow, 2008, Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability, Nat Rev Cancer, 8, 180, 10.1038/nrc2344 Marignol, 2008, Hypoxia in prostate cancer: a powerful shield against tumour destruction?, Cancer Treat Rev, 34, 313, 10.1016/j.ctrv.2008.01.006 McDermott, 2014, Isogenic radiation resistant cell lines: development and validation strategies, Int J Radiat Biol, 90, 115, 10.3109/09553002.2014.873557 Sramkoski, 1999, A new human prostate carcinoma cell line, 22Rv1, In Vitro Cell Dev Biol Anim, 35, 403, 10.1007/s11626-999-0115-4 McDermott, 2016, Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells, Sci Rep, 6, 34796, 10.1038/srep34796 Barbieri, 2013, The mutational landscape of prostate cancer, Eur Urol, 64, 567, 10.1016/j.eururo.2013.05.029 Thomas, 2010, Desperately seeking microRNA targets, Nat Struct Mol Biol, 17, 1169, 10.1038/nsmb.1921 Franken, 2006, Clonogenic assay of cells in vitro, Nat Protoc, 1, 2315, 10.1038/nprot.2006.339 Grün, 2005, MicroRNA target predictions across seven Drosophila species and comparison to mammalian targets, PLoS Comput Biol, 1, e13, 10.1371/journal.pcbi.0010013 Wang, 2008, Prediction of both conserved and nonconserved microRNA targets in animals, Bioinformatics, 24, 325, 10.1093/bioinformatics/btm595 Rupaimoole, 2016, MiRNA deregulation in cancer cells and the tumor microenvironment, Cancer Discov, 6, 235, 10.1158/2159-8290.CD-15-0893 Mueller, 2016, MicroRNAs and their impact on radiotherapy for cancer, Radiat Res, 185, 668, 10.1667/RR14370.1 Shukla, 2016, Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer, Urol Oncol Zhang, 2009, MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT, Cell Cycle, 8, 2756, 10.4161/cc.8.17.9387 Huang, 2010, MiR-210–micromanager of the hypoxia pathway, Trends Mol Med, 16, 230, 10.1016/j.molmed.2010.03.004 Basu, 2015, A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia, PLoS One, 10, e0125560, 10.1371/journal.pone.0125560 Wang, 2014, MiR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance, PLoS One, 9, e98597, 10.1371/journal.pone.0098597 Cochetti, 2016, Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role, Onco Targets Ther, 9, 7545, 10.2147/OTT.S119027 Nishikawa, 2014, Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer, Int J Oncol, 45, 401, 10.3892/ijo.2014.2437 Kumar, 2016, Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening, Oncotarget, 7, 72593, 10.18632/oncotarget.12241 Yaman Agaoglu, 2011, Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer, Tumour Biol, 32, 583, 10.1007/s13277-011-0154-9 Chaudhry, 2013, Identification of radiation-induced microRNA transcriptome by next-generation massively parallel sequencing, J Radiat Res, 54, 808, 10.1093/jrr/rrt014 Chun-Zhi, 2010, MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN, BMC Cancer, 10, 367, 10.1186/1471-2407-10-367 Duan, 2016, Onco-miR-130 promotes cell proliferation and migration by targeting TGFbetaR2 in gastric cancer, Oncotarget, 7, 44522, 10.18632/oncotarget.9936 Wagenseller, 2013, MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab, J Transl Med, 11, 218, 10.1186/1479-5876-11-218 Barron, 2012, Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer, Prostate, 72, 1193, 10.1002/pros.22469 Bian, 2015, Expression of dicer and its related miRNAs in the progression of prostate cancer, PLoS One, 10, e0120159, 10.1371/journal.pone.0120159 Cheng, 2013, Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia, PLoS One, 8, e69239, 10.1371/journal.pone.0069239 Qu, 2014, Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer, PLoS One, 9, e90952, 10.1371/journal.pone.0090952 Osugi, 2015, Prognostic impact of hypoxia-inducible miRNA-210 in patients with lung adenocarcinoma, J oncol, 2015, 8, 10.1155/2015/316745 Haldrup, 2014, Profiling of circulating microRNAs for prostate cancer biomarker discovery, Drug Deliv Transl Res, 4, 19, 10.1007/s13346-013-0169-4 Cheng, 2013, Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia, PLoS One, 8, e69239, 10.1371/journal.pone.0069239 Yang, 2013, Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice, Radiat Oncol, 8, 1, 10.1186/1748-717X-8-102 Hamama, 2014, MiR-210: a potential therapeutic target against radiation-induced enteropathy, Radiother Oncol, 111, 219, 10.1016/j.radonc.2013.10.030 Quero, 2011, MiR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer, Radiother Oncol, 101, 203, 10.1016/j.radonc.2011.05.063 Bach, 1999, RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex, Nat Genet, 22, 394, 10.1038/11970 Her, 2009, Ubiquitin ligase RLIM modulates telomere length homeostasis through a proteolysis of TRF1, J Biol Chem, 284, 8557, 10.1074/jbc.M806702200 Jonkers, 2009, RNF12 is an X-Encoded dose-dependent activator of X chromosome inactivation, Cell, 139, 999, 10.1016/j.cell.2009.10.034 Yaman, 2009, RasGEF1A and RasGEF1B are guanine nucleotide exchange factors that discriminate between Rap GTP-binding proteins and mediate Rap2-specific nucleotide exchange, FEBS J, 276, 4607, 10.1111/j.1742-4658.2009.07166.x Ura, 2006, Enhanced RASGEF1A expression is involved in the growth and migration of intrahepatic cholangiocarcinoma, Clin Cancer Res, 12, 6611, 10.1158/1078-0432.CCR-06-0783 Bos, 1989, Ras oncogenes in human cancer: a review, Cancer Res, 49, 4682 Malumbres, 2003, RAS oncogenes: the first 30 years, Nat Rev Cancer, 3, 459, 10.1038/nrc1097 Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat Rev Cancer, 3, 11, 10.1038/nrc969 Pylayeva-Gupta, 2011, RAS oncogenes: weaving a tumorigenic web, Nat Rev Cancer, 11, 761, 10.1038/nrc3106 Kasid, 1989, Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma, Science, 243, 1354, 10.1126/science.2466340 Hagan, 2000, Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest, Radiat Res, 153, 371, 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2 Gupta, 2001, The Ras radiation resistance pathway, Cancer Res, 61, 4278 Ling, 1989, Radioresistance induced by oncogenic transformation, Radiat Res, 120, 267, 10.2307/3577713 Miller, 1993, Increased radioresistance of ejras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation, Int J Cancer, 53, 302, 10.1002/ijc.2910530222 McKenna, 1990, The role of the H-ras oncogene in radiation resistance and metastasis, Int J Radiat Oncol Biol Phys, 18, 849, 10.1016/0360-3016(90)90407-B Bernhard, 1998, Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes, Cancer Res, 58, 1754 Bernhard, 2000, Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines, Cancer Res, 60, 6597